The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure -: An analysis of the Candesartan in Heart failure:: Assessment of Reduction in Mortality and Morbidity (CHARM) program
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure -: An analysis of the Candesartan in Heart failure:: Assessment of Reduction in Mortality and Morbidity (CHARM) program
复制标题
DOI：
10.1001/archinte.168.15.1699
复制
发表时间：
2008-08-11
影响因子：
--
通讯作者：
Yusuf, Salim
中科院分区：
文献类型：
--
作者：
Gerstein, Hertzel C.;Swedberg, Karl;Yusuf, Salim
背景资料：在糖尿病患者和非糖尿病患者中观察到血红蛋白A（1c）（HbA（1c））水平与心血管（CV）事件之间存在进行性关系。据我们所知，这种关系在有症状的慢性心力衰竭（HF）患者的性质尚未studyed.Methods：共2412名参与者（907与先前的糖尿病）在坎地沙坦在心力衰竭：评估降低死亡率和死亡率（CHARM）计划与至少1 HbA（1C）水平进行了随访，中位数为34个月。主要结局（CV死亡或HF住院）、CV死亡和总死亡率的发生率根据通常HbA（1c）水平的八分之一计算，范围为5.8%或更低至8.6%以上。调整和未调整的风险比每上升1%的HbA（1c）levels.Results：共99.6%的合格参与者进行了随访，直到他们制定的结果或研究完成。主要复合终点、CV死亡、因HF恶化住院和总死亡率的风险随着普通HbA（1c）水平的升高而逐渐升高（P趋势
Background: A progressive relationship between hemoglobin A(1c) (HbA(1c)) levels and cardiovascular (CV) events has been observed in persons with and without diabetes. To our knowledge, the nature of such a relationship in patients with symptomatic chronic heart failure (HF) has not been studied.Methods: A total of 2412 participants (907 with prior diabetes) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program with at least 1 HbA(1c) level were followed up for a median of 34 months. The incidence of the primary outcome (CV death or HF hospitalization) I CV death, and total mortality was calculated according to eighths of the usual HbA(1c) level ranging from 5.8% or less to greater than 8.6%. Adjusted and unadjusted hazard ratios per 1% rise in HbA(1c) levels were also calculated.Results: A total of 99.6% of eligible participants were followed up until they developed an outcome or the study finished. The risk of the primary composite outcome, CV death, hospitalization for worsening HF, and total mortality rose progressively with higher levels of usual HbA(1c) (P for trend